- Home
- GITS vs MYNZ Comparison
GITS vs MYNZ Comparison
Compare GITS & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GITS
- MYNZ
- Stock Information
- Founded
- GITS 2018
- MYNZ 2021
- Country
- GITS South Korea
- MYNZ Germany
- Employees
- GITS N/A
- MYNZ N/A
- Industry
- GITS
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- GITS
- MYNZ Health Care
- Exchange
- GITS Nasdaq
- MYNZ Nasdaq
- Market Cap
- GITS 7.0M
- MYNZ 7.9M
- IPO Year
- GITS N/A
- MYNZ 2021
- Fundamental
- Price
- GITS $2.07
- MYNZ $1.68
- Analyst Decision
- GITS
- MYNZ Buy
- Analyst Count
- GITS 0
- MYNZ 2
- Target Price
- GITS N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- GITS 16.8K
- MYNZ 73.5K
- Earning Date
- GITS 11-19-2025
- MYNZ 09-26-2025
- Dividend Yield
- GITS N/A
- MYNZ N/A
- EPS Growth
- GITS N/A
- MYNZ N/A
- EPS
- GITS N/A
- MYNZ N/A
- Revenue
- GITS $29.00
- MYNZ $659,935.00
- Revenue This Year
- GITS N/A
- MYNZ $26.06
- Revenue Next Year
- GITS N/A
- MYNZ $4.97
- P/E Ratio
- GITS N/A
- MYNZ N/A
- Revenue Growth
- GITS N/A
- MYNZ N/A
- 52 Week Low
- GITS $0.87
- MYNZ $1.30
- 52 Week High
- GITS $9.78
- MYNZ $16.04
- Technical
- Relative Strength Index (RSI)
- GITS 38.31
- MYNZ 54.01
- Support Level
- GITS $2.21
- MYNZ $1.55
- Resistance Level
- GITS $2.47
- MYNZ $1.75
- Average True Range (ATR)
- GITS 0.14
- MYNZ 0.11
- MACD
- GITS -0.03
- MYNZ 0.02
- Stochastic Oscillator
- GITS 2.97
- MYNZ 79.03
About GITS Global Interactive Technologies Inc. Common Stock
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.